65,437 trials
Leukemia
Primary: Maximum Tolerated Dose (MTD) Oxaliplatin — 25 mg/m^2
Contraception
Primary: Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) — 1.754; 3.005; 1.963; 3.092 Pregnancies per 100 woman years
Healthy Postmenopausal Females
Primary: Maximum Observed Plasma Concentration of NOMAC (Cmax of NOMAC) — 6.22; 4.51; 8.03; 7.20 ng/mL
Infertility
Primary: The Number of Participants Who Achieved Clinical Pregnancy in a Transfer Cycle — 17; 7 participents — p=0.023
Recurrent Abortion
Primary: Live Birth Rate = (Number of Live Births / Total Number of Pregnancies) — 24; 20 Percentage of pregnancies
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — -0.02; -0.56; -0.59 percentage of Glycosylated Hemoglobin — p=<0.001
Cataracts
Primary: Aqueous PGE2 Inhibition — 288.7; 320.4; 224.8 pg/ml
Thromboembolism · Venous Thromboembolism
Primary: Number of Participants Receiving Fondaparinux in the Indicated Therapy Intervals — 6; 0; 1; 3 participants
Post Operative Anterior Chamber Inflammation (Flare)
Primary: Anterior Chamber Inflammation (Flare) — 24.48; 21.93 photon count per msec (pc/ms)
Migraine Disorders
Primary: Percentage of Participants Who Reported Pain Relief at 120 Minutes Post-Treatment — 38.6; 31.1 percentage of participants — p=0.345
Lymphoma, Follicular
Primary: Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab) — 6; 9; 10; 7 participants
Cataracts
Primary: Peak Aqueous Penetration — 688.87; 67.64; 447.1 ng/ml
Fungal Infection
Primary: Number of Participants With a Significant Drug-related Adverse Experience — 3; 6 Participants
Astigmatism · Myopia
Primary: Quality of Vision (Crisp and Clear) — 8.8; 8.6 units on a scale
Skin Infections, Bacterial
Primary: Number of Participants Achieving Clinical Response at Follow-up Who Had Methicillin-resistant Staphlococcus Aureus (MRSA) as a Baseline Pathogen — 41; 32 participants